Evidence map›Paper›PMID 29995913›Full record

ArticlePloS one2018

Identification of novel diabetes impaired miRNA-transcription factor co-regulatory networks in bone marrow-derived Lin-/VEGF-R2+ endothelial progenitor cells.

Mohammad R Irhimeh, Mohamed Hamed, Daniel Barthelmes, Yvonne Gladbach, Volkhard Helms, Weiyong Shen, Mark C Gillies

Abstract read
In one paragraph

Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Mohammad R IrhimehCell and Tissue Therapies WA, Royal Perth Hospital; Medical Unit, Fiona Stanley Fremantle Hospitals Group, Perth, WA Australia.ORCID 0000-0002-2190-9657
Mohamed HamedInstitute for Biostatistics and Informatics in Medicine and Ageing Research, Rostock University Medical Centre, Rostock University, Rostock, Germany.
Daniel BarthelmesSave Sight Institute, Sydney Hospital and Sydney Eye Hospital, Central Clinical School, The University of Sydney, Sydney, NSW Australia.
Yvonne GladbachInstitute for Biostatistics and Informatics in Medicine and Ageing Research, Rostock University Medical Centre, Rostock University, Rostock, Germany.
Volkhard HelmsCenter for Bioinformatics, Saarland University, Saarbrücken, Germany.
Weiyong ShenSave Sight Institute, Sydney Hospital and Sydney Eye Hospital, Central Clinical School, The University of Sydney, Sydney, NSW Australia.
Mark C GilliesSave Sight Institute, Sydney Hospital and Sydney Eye Hospital, Central Clinical School, The University of Sydney, Sydney, NSW Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Endothelial progenitor cells (EPCs) are a group of rare cells that play an important role in the repair of injured vascular endothelial cells and assist in reperfusion of ischemic tissue. Decreased production and/or loss of function of EPCs are associated with diabetic vasculopathy. The molecular mechanisms by which diabetes impairs EPCs remain unclear. We conducted microarray experiments followed by integrative regulatory analysis on cells isolated from Akita diabetic mice (18-weeks after onset of diabetes) and age-matched non-diabetic controls. Two types of cells were isolated from mice bone marrow; Lin+ cells and Lin-/VEGF-R2+ EPCs. RNA was hybridized to mouse WG-6 V2 beadchips followed by comprehensive gene network analysis and computational validation of the obtained results. In total, 80 genes were exclusively DE between non-diabetic Lin-/VEGF-R2+ EPCs and diabetic Lin-/VEGF-R2+ EPCs, of which the 3 genes Clcnka, Pik3c2a, and Ptf1a are known to be associated with diabetic complications. Further analysis led to the establishment of a TF-miRNA mediated regulatory network specific to diabetic Lin-/VEGF-R2+ EPCs and to identify 11 central-hub TFs (Tbp, Ahr, Trp53, Gata1, Foxo1, Foxo4, Yy1, Max, Pparg, Myc, Cebpa), and 2 miRNAs (mir-139-5p, mir-709) that might act as putative genomic drivers of diabetic pathogenesis in Lin-/VEGF-R2+ EPCs. Moreover, we identified multiple TF-miRNA co-regulatory network motifs for which we validated their contribution to diabetic Lin-/VEGF-R2+ EPCs in terms of statistical significance and relevance to biological evidence. Our findings suggest that diabetic Lin-/VEGF-R2+ EPCs have specifically altered signature genes and miRNAs that render their capacity to proliferate and differentiate.

Indexed as

AnimalsBone Marrow CellsDiabetes Mellitus, ExperimentalEndothelial Progenitor CellsGene Expression RegulationGene Regulatory NetworksMaleMice, TransgenicMicroRNAsTranscription FactorsVascular Endothelial Growth Factor Receptor-2Kdr protein, mouseMicroRNAsTranscription FactorsVascular Endothelial Growth Factor Receptor-2

Identifiers

PMID29995913
PMCPMC6040716

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.